Apyx Medical Expects 2024 Revenues Of $46.6M-$47.6M Compared To Prior Guidance Of $50.6M-$52.1M Versus Consensus Of $50.767M

Apyx Medical預計2024年的收入爲4660萬美元，較之前的指導收入爲5060萬美元有所下降，而與市場預期的5076.7萬美元相比達到4760萬美元。

Benzinga · 2024/11/08 20:12

The Company is updating its financial guidance for the year ending December 31, 2024 to:

公司正在更新截至2024年12月31日的財務指引：

Total revenue is now expected to be in the range of $46.6 million to $47.6 million, representing a decrease from 2023 of approximately 11% to 9%. The Company's prior guidance range for total revenue was $50.6 million to $52.1 million.
- Total revenue guidance assumes:
  - Revenue from the Advanced Energy segment is now expected to be in the range of $37.2 million to $38.2 million, representing a decrease from 2023 of approximately 14% to 12%. The Company's prior guidance range for Advanced Energy revenue was $41.6 million to $43.1 million.
  - Revenue from the OEM segment is now expected to be approximately $9.4 million, representing growth of approximately 5% from 2023. The Company's prior guidance for OEM revenue was approximately $9.0 million.
Net loss attributable to stockholders is now expected to be approximately $25.0 million, compared to $18.7 million for the year ended December 31, 2023. The Company's prior guidance range for net loss attributable to stockholders was $24.5 million to $23.5 million.

預計總收入現在將在$4660萬至$4760萬的區間內，較2023年下降約11%至9%。公司此前對總收入的指引區間爲$5060萬至$5210萬。
- 總收入指引假定：
  - Advanced能源部門的營業收入現預計將在$3720萬至$3820萬的區間內，較2023年下降約14%至12%。公司先前對Advanced能源收入的指引區間爲$4160萬至$4310萬。
  - OEm部門的營業收入現預計將約爲$940萬，較2023年增長約5%。公司先前對OEm收入的指引約爲$900萬。
歸屬股東的淨損失現預計約爲$2500萬，較2023年12月31日年度的$1870萬有所增加。公司先前對歸屬股東的淨損失的指引區間爲$2450萬至$2350萬。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

風險及免責聲明